Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr. Makarand Jawadekar, Ph.D
Independent Pharma Professional
About the author:
Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at Pfizer Inc. based in Groton-New London Connecticut for 28 consecutive years. He worked as a Director, Portfolio Management. During his career at Pfizer, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota..Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011.
Posts by Dr. Makarand Jawadekar, Ph.D
Posted on November 7th, 2016 in Pharma R&D
For many of the last five decades, India has been known as the largest exporter of generic drugs, particularly to the United States. However, today, in 2016, India is getting to be known for a bit more than that: (more…)
Posted on October 19th, 2016 in Pharma R&D
For years, the pharmaceutical or biopharma industry and the information technology (IT) sector seemed to be more or less separate entities. This has certainly changed in more recent times. (more…)
Posted on September 26th, 2016 in Pharma R&D
The media as of late has given a lot of coverage to the “price gouging” that pharmaceutical company Mylan engaged in with its injection device EpiPen. (more…)
Posted on August 26th, 2016 in Chemistry
In January of 2015, President Barack Obama launched the Precision Medicine Initiative, which brought to the forefront the growing understanding and need for individually tailored and customized treatments for patients.